OasisLMS

Cases in Precision Oncology: Complex In-frame DELINS in Cancer

Tuesday, June 24^th, 2025

11:00am-12:00pm ET

www.acmgeducation.net

Course Description

Complex In-frame Variants in Cancer: How to recognize and communicate these variants when your informatics pipeline does not

Dr. Kandelaria (Ande) Rumilla, Beth Pitel, and Kaitlyn Paxton are some of the technical experts that work behind the scenes at Mayo Clinic’s Genomic Technologies clinical laboratory to investigate genomic and transcriptomic variants at a sequence level.  In this session, the team will highlight the importance of understanding the genomic frame status in solid tumor testing.

Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Agenda

Presentations followed by live Q&A. 

Learning Objectives

At the conclusion of this session, participants should be able to:

1. List 3 genes that are known to have actionable in-frame mutations in cancer.
2. Describe how 2 frameshift mutations may or may not have an overall in-frame effect.
3. Explain how interpreting variants as in-frame or out-of-frame can alter patient management.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

• Financial Disclosures and Mitigation Procedure
• ACMG Content Validation Policy
• ACMG Content Branding Policy

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclaimer

ACMG educational programs are designed primarily as an educational tool for healthcare professionals who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse, or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or test, a healthcare professional should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.

Questions regarding CE credit should be directed to education@acmg.net